Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > ATE

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 01, 2020 4:07pm

143 Views

Post# 32011778

RE:RE:RE:ATE

NotBornLastNite wrote: dilution is not the answer. ATE has their big boy pants on now and I believe is positioned to encourage, entice bigger players to the game. Patience is the game plan moving foreward. IMO

Agreed ... patience is the name of the game.

But - they need to have a well thought out back-up plan if Big Pharma decides to wait. Hoping at least one Big Pharma decides not to wait and jumps in early. That would play nicely into Antibe's hands.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China